Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process
Piers E.M. Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan E. Kolitz, Jacqueline Barrientos, Steven L. Allen, Kanti R. Rai, Thomas MacCarthy, Charles C. Chu, Nicholas Chiorazzi
Piers E.M. Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan E. Kolitz, Jacqueline Barrientos, Steven L. Allen, Kanti R. Rai, Thomas MacCarthy, Charles C. Chu, Nicholas Chiorazzi
View: Text | PDF
Research Article Hematology Immunology

Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process

  • Text
  • PDF
Abstract

Xenografting primary tumor cells allows modeling of the heterogeneous natures of malignant diseases and the influences of the tissue microenvironment. Here, we demonstrate that xenografting primary chronic lymphocytic leukemia (CLL) B lymphocytes with activated autologous T cells into alymphoid mice results in considerable CLL B cell division and sizable T cell expansion. Nevertheless, most/all CD5+CD19+ cells are eventually lost, due in part to differentiation into antibody-secreting plasmablasts/plasma cells. CLL B cell differentiation is associated with isotype class switching and development of new IGHV-D-J mutations and occurs via an activation-induced deaminase-dependent pathway that upregulates IRF4 and Blimp-1 without appreciable levels of the expected Bcl-6. These processes were induced in IGHV-unmutated and IGHV-mutated clones by Th1-polarized T-bet+ T cells, not classical T follicular helper (Tfh) cells. Thus, the block in B cell maturation, defects in T cell action, and absence of antigen-receptor diversification, which are often cardinal characteristics of CLL, are not inherent but imposed by external signals and the microenvironment. Although these activities are not dominant features in human CLL, each occurs in tissue proliferation centers where the mechanisms responsible for clonal evolution operate. Thus, in this setting, CLL B cell diversification and differentiation develop by a nonclassical germinal center–like reaction that might reflect the cell of origin of this leukemia.

Authors

Piers E.M. Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan E. Kolitz, Jacqueline Barrientos, Steven L. Allen, Kanti R. Rai, Thomas MacCarthy, Charles C. Chu, Nicholas Chiorazzi

×

Figure 6

IRF4 and Blimp-1 protein are expressed during CLL B cell differentiation and diversification.

Options: View larger image (or click on image) Download as PowerPoint
IRF4 and Blimp-1 protein are expressed during CLL B cell differentiation...
(A) Upper panels show FC of undivided CFSE-labeled human (h) CD45+CD5+CD19+ cells with companion IH images of IRF4 and PAX5 (day 3). Lower panels show FC of dividing CFSE-labeled hCD45+CD5+CD19+ cells with companion IH images of IRF4 and PAX5 (day 14). Scale bar: 50 μm. Representative data of mice sampled from 5 independent experiments. (B) IRF4 staining is seen within (arrow, upper left) and outside of (*, upper left) CD20+PAX5+PVAs, being expressed dimly by CD20+ cells and more intensely by cIg+ cells. Upper panels: dual IH images of CD20 (black) and IRF4 (brown); left hand panel (scale bar: 250 μm), with high-power view of area marked with arrow on right (scale bar: 50 μm). Lower panels: dual IH images of Igκ (black) and IRF4 (brown); left hand panel (scale bar: 250 μm), with high-power view of area marked with arrow on right (scale bar: 50 μm). Representative data of dual IH performed on mice sampled from 5 independent experiments. (C) Dual IH of spleen-residing cells 6 weeks following transfer indicates chronic lymphocytic leukemia (CLL) plasmablasts/plasma cells express IRF4 and Blimp-1. Scale bar: 10 μm. Representative data of mice sampled from 6 independent experiments. FC, flow cytometry; PVA, perivascular aggregate; IH, immunohistology; cIg, cytoplasmic immunoglobulin.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts